Lv11
78 积分 2026-02-06 加入
Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial
18分钟前
求助中
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
1个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
2个月前
已完结
P3.12.64 Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation EGFR-TKI Failure: SACHI Study Insights
5个月前
已关闭
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
5个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
5个月前
已完结
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
5个月前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
5个月前
已完结
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
6个月前
已完结
Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making
6个月前
已完结